03.31.26 -- February 2026 — CDMO Opportunities And Threats Report

Accelerate the development of next-generation cancer therapies with optimized ADC solutions designed to meet the diverse needs of global clients.

Explore how PEG selection shapes drug development success by understanding the benefits of expert CDMO partnerships that deliver custom solutions to enhance your small molecule program.

Review the elements of a complex process, prone to misconceptions and pitfalls, to find the “right human tissue” that will yield the desired cell quality and quantity and pass BLA approval.

Discover a standardized yet flexible modular biomanufacturing system designed to accelerate timelines, improve scalability, and enhance quality while reducing costs and environmental impact.

Characterizing Fab and Fc-Fusion proteins and developing robust manufacturing processes can help usher them to market and provide new treatment options for diseases that are challenging to treat.

Mass spectrometry is now a fast, sensitive tool that supports drug discovery, development, quality control, and lifecycle management through detailed molecular analysis.

Examine a platform that boosts AAV yields up to 30-fold, improves capsid quality, and reduces costs by 85%, enabling scalable, contamination-free manufacturing for advanced gene therapy applications.

Uncover a disposable pen that is a proven, globally adopted drug delivery platform with over 175 million units sold, supporting diverse therapies in 40+ countries.

Variability reduction programs improve biomanufacturing by controlling raw‑material complexity, optimizing critical attributes, and boosting productivity through data‑driven partnerships.

Gain insight into how we were able to provide seamless technology transfers and uninterrupted production to deliver critical therapies efficiently and reliably to patients.

What does it take to move a molecule from concept to clinic? It’s often more steps – and more time – than biotechs think.